Advertisement
FHTX vs LCTX
Which Stock Would AI Choose? Foghorn Therapeutics (FHTX) vs. Lineage Cell Therapeutics (LCTX) Stock Comparison
Key Takeaways
- Both FHTX and LCTX are clinical-stage biotechnology companies that have each fallen roughly 35% or more year-to-date, reflecting broad pressure on small-cap biotech.
- Foghorn recently ended its Eli Lilly collaboration and halted its lead partnered asset, triggering layoffs and multiple analyst downgrades, while pivoting to an earlier-stage, wholly owned pipeline.
- Lineage maintains a "Strong Buy" consensus from analysts, supported by its Roche/Genentech-partnered OpRegen program and a cash runway into 2028.
- FHTX carries sharper negative momentum after a steep sell-off, while LCTX shows a higher average analyst price target but trades below $1.10 per share.
- The comparison highlights two very different risk profiles: a recently restructured precision-medicine developer versus a cell-replacement therapy platform company.
Introduction
Investors screening the small-cap biotechnology space often encounter FHTX and LCTX as two companies navigating very different phases of development. Foghorn Therapeutics is a precision-medicine developer focused on the chromatin regulatory system that governs gene expression, while Lineage Cell Therapeutics is building cell replacement therapies for degenerative conditions. A stock comparison between the two is useful for traders and long-term investors alike, because their recent market positioning, momentum, and catalyst timelines diverge meaningfully. Understanding each company's relative performance, financing position, and pipeline risk can help clarify which profile aligns with a given risk tolerance.
FHTX Overview and Recent Performance
Foghorn Therapeutics, based in Cambridge, Massachusetts, develops precision medicines targeting the chromatin regulatory system through its proprietary Gene Traffic Control platform. The company's outlook shifted substantially in recent weeks after it announced the end of its oncology collaboration with Eli Lilly. Under that partnership, which began in 2021 with an upfront payment and equity investment from Lilly, the lead program FHD-909 (a SMARCA2 inhibitor) showed a favorable safety profile in Phase 1 testing but insufficient efficacy to justify further development.
The discontinuation triggered a sharp repricing of FHTX, sending shares toward multi-year lows. Foghorn also announced a workforce reduction of roughly 40% and a strategic pivot toward wholly owned programs, including an EP300 degrader, a CBP degrader, and an oral immunology program, with restructuring expected to extend its cash runway into the second half of 2029. Several analysts lowered price targets or downgraded the stock to neutral, while others maintained buy ratings citing the value of the remaining pipeline. This divergence underscores the uncertainty surrounding the company's near-term catalysts.
LCTX Overview and Recent Performance
Lineage Cell Therapeutics, headquartered in Carlsbad, California, develops allogeneic (off-the-shelf) cell replacement therapies built on its AlloSCOPE platform. Its most advanced asset, OpRegen, is a retinal pigment epithelial cell therapy for dry age-related macular degeneration that is partnered with Roche and Genentech. The broader pipeline includes OPC1 for spinal cord injury, ReSonance for auditory neuropathy, and ILT1 for type 1 diabetes.
In recent market activity, LCTX has traded below $1.10 per share, with the stock down significantly over the past several months despite maintaining a "Strong Buy" consensus rating and an average price target several times above its current price. The company reported modest revenue and a wider net loss in its most recent quarterly results, while management has emphasized disciplined spending, a cash runway into 2028, and eligibility for milestone payments under the Roche/Genentech agreement. Relative to FHTX, Lineage's positioning reflects a broader, partnered pipeline but also dependence on clinical progress from its largest collaborator.
Trending AI Robots
For traders seeking a data-driven edge in volatile names like these, Tickeron's Trending AI Robots page curates a selection of algorithmic trading strategies designed to adapt to changing market conditions. Tickeron hosts hundreds of AI trading bots that collectively monitor and trade thousands of different tickers, each with distinct trading styles, strategies, timeframes, performance statistics, and watchlists. Rather than listing every available bot, the Trending section highlights only those currently best suited to prevailing market conditions. This curated approach helps users focus on strategies with relevant momentum rather than sifting through the full catalog. Explore the Trending AI Robots to see which automated approaches are drawing attention in the current environment.
Head-to-Head Comparison
Although both companies operate in biotechnology, their business models differ fundamentally. Foghorn is a precision-medicine developer pursuing small-molecule and protein-degradation approaches to cancers and inflammatory disease, and it has just shifted to a fully preclinical, wholly owned pipeline. Lineage, by contrast, is a cell-therapy platform company with a mix of wholly owned and partnered programs, anchored by a high-profile collaboration with Roche and Genentech.
On momentum, FHTX carries the weaker recent trend after its collaboration termination and downgrade cycle, while LCTX has also declined but retains a stronger analyst consensus. Growth drivers differ as well: Foghorn's near-term narrative rests on preclinical validation and future IND (Investigational New Drug) filings, whereas Lineage's is tied to partner-led clinical milestones and manufacturing scale-up. Risk factors include Foghorn's reduced headcount and earlier-stage focus versus Lineage's reliance on partner execution and its sub-$1 trading range, which raises volatility considerations. Neither stock is profitable, and both depend on cash runway discipline.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor LCTX in the current comparison, primarily because its trend profile is comparatively more stable and it retains a stronger, more consistent analyst outlook backed by a partnered, revenue-eligible pipeline. FHTX, while potentially undervalued on a cash basis, currently exhibits sharper negative momentum, elevated downgrade activity, and fewer near-term catalysts following its restructuring. That said, any AI-based assessment remains probabilistic: Foghorn's cheaper valuation and refocused pipeline could re-rate quickly if a new program gains traction, while Lineage's fate is heavily tied to external clinical milestones. The relative positioning suggests Lineage holds a modest edge on stability and catalysts, but both names carry meaningful biotech-specific risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FHTX is a StrongBuy and LCTX is a StrongBuy.
FHTX sees its Stochastic Oscillator recovers from oversold territory
On October 20, 2026, the Stochastic Oscillator for FHTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 58 instances where the indicator left the oversold zone. In 54 of the 58 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on FHTX as a result. In 67 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for FHTX just turned positive on October 16, 2026. Looking at past instances where FHTX's MACD turned positive, the stock continued to rise in 35 of 36 cases over the following month. The odds of a continued upward trend are 90%.
Following a +9.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 235 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for FHTX moved below the 200-day moving average on October 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.466) is normal, around the industry mean (2.973). P/E Ratio (-2.020) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. FHTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
LCTX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for LCTX turned positive on October 08, 2026. Looking at past instances where LCTX's MACD turned positive, the stock continued to rise in 46 of 51 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 63 of 74 cases where LCTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +9.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in 158 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
LCTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LCTX as a result. In 99 of 118 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for LCTX entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.089) is normal, around the industry mean (2.973). P/E Ratio (-7.036) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.060) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. LCTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
FHTX | LCTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 2 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 94 | 77 | |
P/E GROWTH RATING 1..100 | 8 | 25 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
FHTX's Valuation (24) in the null industry is in the same range as LCTX (26). This means that FHTX’s stock grew similarly to LCTX’s over the last 12 months.
FHTX's Profit vs Risk Rating (100) in the null industry is in the same range as LCTX (100). This means that FHTX’s stock grew similarly to LCTX’s over the last 12 months.
LCTX's SMR Rating (98) in the null industry is in the same range as FHTX (100). This means that LCTX’s stock grew similarly to FHTX’s over the last 12 months.
LCTX's Price Growth Rating (77) in the null industry is in the same range as FHTX (94). This means that LCTX’s stock grew similarly to FHTX’s over the last 12 months.
FHTX's P/E Growth Rating (8) in the null industry is in the same range as LCTX (25). This means that FHTX’s stock grew similarly to LCTX’s over the last 12 months.
| FHTX | LCTX | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 89% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| Advances ODDS (%) | 3 days ago 86% | 9 days ago 75% |
| Declines ODDS (%) | 11 days ago 84% | 5 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FHTX’s FA Score shows that 2 FA rating(s) are green while LCTX’s FA Score has 2 green FA rating(s).
- FHTX’s FA Score: 2 green, 3 red.
- LCTX’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FHTX’s TA Score shows that 5 TA indicator(s) are bullish while LCTX’s TA Score has 4 bullish TA indicator(s).
- FHTX’s TA Score: 5 bullish, 3 bearish.
- LCTX’s TA Score: 4 bullish, 3 bearish.
Price Growth
FHTX (@Biotechnology) experienced а +6.35% price change this week, while LCTX (@Biotechnology) price change was -0.54% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was -16.27%, and the average quarterly price growth was -16.72%.
Reported Earning Dates
FHTX is expected to report earnings on Nov 04, 2026.
LCTX is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (+1.28% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
FHTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, FHTX has been loosely correlated with ARVN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if FHTX jumps, then ARVN could also see price increases.
| Ticker / NAME | Correlation To FHTX | 1D Price Change % | ||
|---|---|---|---|---|
| FHTX | 100% | -1.47% | ||
| ARVN - FHTX | 41% Loosely correlated | +2.18% | ||
| LCTX - FHTX | 40% Loosely correlated | +3.52% | ||
| DNLI - FHTX | 39% Loosely correlated | -0.11% | ||
| IMTX - FHTX | 39% Loosely correlated | -1.95% | ||
| VYGR - FHTX | 38% Loosely correlated | -7.92% | ||
More | ||||
LCTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To LCTX | 1D Price Change % | ||
|---|---|---|---|---|
| LCTX | 100% | +3.52% | ||
| MDGL - LCTX | 43% Loosely correlated | -1.01% | ||
| IMNM - LCTX | 43% Loosely correlated | +1.44% | ||
| VIR - LCTX | 42% Loosely correlated | -1.32% | ||
| FHTX - LCTX | 41% Loosely correlated | -1.47% | ||
| NKTX - LCTX | 40% Loosely correlated | -0.57% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DGT | 189.60 | -0.11 | -0.06% |
| State Street SPDR Global Dow ETF (DGT) | |||
| CGBL | 36.81 | -0.19 | -0.51% |
| Capital Group Core Balanced ETF (CGBL) | |||
| ENHU | 28.47 | -0.39 | -1.33% |
| iShares Enhanced Large Cap Core Active ETF (ENHU) | |||
| PEXL | 70.01 | -1.90 | -2.65% |
| Pacer US Export Leaders ETF (PEXL) | |||
| QQQY | 21.04 | -0.70 | -3.22% |
| Defiance Nasdaq 100 Weekly Distribution ETF (QQQY) | |||